Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 4/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12380917 | 0.92 | CA2 (0.39) | LMNASLC6A6CYP2C19BLMCA2 | |
| SCHEMBL13944642 | 0.87 | APP (0.48) | LMNASLC6A6CYP2C19BLMCA2 | |
| SCHEMBL4183162 | 0.83 | LMNA (0.46) | LMNASLC6A6CYP2C19BLMCA2 | |
| SCHEMBL6913359 | 0.81 | LMNA (0.44) | LMNASLC6A6CYP2C19BLMCA2 | |
| SCHEMBL15808676 | 0.80 | CA2 (0.42) | LMNACA2CA1MEN1KMT2A | |
| SCHEMBL7531907 | 0.80 | MEN1 (0.38) | LMNASLC6A6CYP2C19BLMCA2 | |
| SCHEMBL10886005 | 0.79 | APP (0.50) | LMNASLC6A6CYP2C19BLMCA2 | |
| SCHEMBL23929057 | 0.79 | ACP1 (0.38) | LMNASLC6A6CYP2C19BLMAPP | |
| SCHEMBL4809608 | 0.79 | ALDH1A1 (0.36) | LMNASLC6A6CYP2C19BLMAPP | |
| SCHEMBL30407466 | 0.79 | L3MBTL1 (0.47) | LMNASLC6A6CYP2C19BLMCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0618235-B1 | Process for the synthesis of semisynthetic glycosaminoglycans containing alpha-L-galacturonic acid substituted with nucleophilic radicals in position 3 | ALFA WASSERMANN SPA (IT) | 1997-07-23 | — | — | EP | claimed |
| EP-0565863-B1 | Semi-synthetic glycosaminoglycans with heparin or heparan structure of alpha-L-iduronic-2-0-sulfate acid modified in position 2 | ALFA WASSERMANN SPA (IT) | 1997-06-18 | — | — | EP | claimed |
| EP-0565862-B1 | Semi-synthetic glycosaminoglycans containing alpha-L-galacturonic acid substituted with nucleophilic radicals in position 3 | ALFA WASSERMANN SPA (IT) | 1997-06-18 | — | — | EP | claimed |
| EP-0618234-B1 | Process for the synthesis of semisynthetic glycosaminoglycans with heparin or heparan structure modified in position 2 of the alpha-L-iduronic-2-0-sulfate acid | ALFA WASSERMANN SPA (IT) | 1997-06-04 | — | — | EP | claimed |
| EP-0467856-B1 | Aminoalkanesulfonic acid derivatives and pharmaceutical compositions for use in preventing or treating heart diseases | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 1997-03-19 | — | — | EP | claimed |
| US-5430133-A | Semi-synthetic glycosaminoglycans with heparin or heparan structure of α-L-iduronic-2-O-sulfate acid modified in position 2 | ALFA WASSERMANN S.P.A. (IT) | 1995-07-04 | — | — | US | claimed |
| US-5410039-A | Process for the synthesis of glycosaminoglycans containing α-L-galacturonic acid substituted with nucleophilic groups in position 3 | ALFA WASSERMANN S.P.A. (IT) | 1995-04-25 | — | — | US | claimed |
| US-5405949-A | Process for the synthesis of glycosaminoglycans with heparin or heparan structure modified in position 2 of the α-L-iduronic-2-O-sulfate acid | ALFA WASSERNANN S.P.A. (IT) | 1995-04-11 | — | — | US | claimed |
| EP-0618235-A1 | Process for the synthesis of semisynthetic glycosaminoglycans containig alpha-L-galacturonic acid substituted with nucleophilic radicals in position 3 | ALFA WASSERMANN S.p.A. (IT) | 1994-10-05 | — | — | EP | claimed |
| EP-0618234-A1 | Process for the synthesis of semisynthetic glycosaminoglycans with heparin or heparan structure modified in position 2 of the alpha-L-iduronic-2-0-sulfate acid | ALFA WASSERMANN S.p.A. (IT) | 1994-10-05 | — | — | EP | claimed |
| EP-0565863-A2 | Semi-synthetic glycosaminoglycans with heparin or heparan structure of alpha-L-iduronic-2-0-sulfate acid modified in position 2 | ALFA WASSERMANN S.p.A. (IT) | 1993-10-20 | — | — | EP | claimed |
| EP-0565862-A2 | Semi-synthetic glycosaminoglycans containing alpha-L-galacturonic acid substituted with nucleophilic radicals in position 3 | ALFA WASSERMANN S.p.A. (IT) | 1993-10-20 | — | — | EP | claimed |
| EP-0467856-A2 | Aminoalkanesulfonic acid derivatives and pharmaceutical compositions for use in preventing or treating heart diseases | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1992-01-22 | — | — | EP | claimed |
| JP-4077423-A | — | — | None | — | — | JP | disclosed |
| EP-2470553-B1 | POLYHYDROXYLATED BILE ACIDS FOR TREATMENT OF BILIARY DISORDERS | QING BILE THERAPEUTICS INC (CA) | 2024-06-19 | — | — | EP | disclosed |
| US-11980645-B2 | Bile acids and use in disease treatment | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-05-14 | — | — | US | disclosed |
| EP-0565863-A2 | Semi-synthetic glycosaminoglycans with heparin or heparan structure of alpha-L-iduronic-2-0-sulfate acid modified in position 2 | ALFA WASSERMANN S.p.A. (IT) | 1993-10-20 | — | — | EP | disclosed |
| EP-0565862-A2 | Semi-synthetic glycosaminoglycans containing alpha-L-galacturonic acid substituted with nucleophilic radicals in position 3 | ALFA WASSERMANN S.p.A. (IT) | 1993-10-20 | — | — | EP | disclosed |
| JP-H0477423-A | THERAPEUTIC AGENT FOR HEART DISEASE | NIPPON ZOKI PHARMACEUT CO LTD | 1992-03-11 | — | — | JP | disclosed |
| EP-0472205-A1 | Assays using a soluble fibrin-like monomer | New York Blood Center, Inc. (US) | 1992-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11980645-B2 | Bile acids and use in disease treatment | SLC10A2, NR1H4, GPBAR1 | LMNA 2285/4885SLC6A6 428/4885CYP2C19 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.